Physician profile
Brian T Chu
NPI 1992943476
$2,638.02
in general payments reported to CMS, 2019-2025
21 companies · $769 in 2025
The $769 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $135 · 2022: $441 · 2023: $351 · 2024: $943 · 2025: $769.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,049 · Education: $13.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,048.97 |
| Education | $13.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $403.02 | 2019-2025 | Lokelma, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $338.61 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $227.21 | 2024-2025 | |
| Vifor Pharma, INC. | $186.43 | 2022-2025 | Veltassa |
| Ardelyx, INC. | $173.27 | 2024-2025 | Ibsrela |
| Lilly USA, LLC | $162.70 | 2023-2025 | Jardiance |
| Amgen INC. | $161.84 | 2025 | Krystexxa, Tavneos |
| Otsuka America Pharmaceutical, INC. | $144.94 | 2022-2024 | Jynarque |
| Janssen Pharmaceuticals, INC | $117.73 | 2019-2024 | Xarelto |
| Pfizer INC. | $110.39 | 2024 | |
| Daiichi Sankyo INC. | $101.82 | 2022-2024 | Injectafer |
| Travere Therapeutics, INC. | $88.55 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $74.49 | 2024-2025 | Jardiance |
| Melinta Therapeutics, LLC | $68.70 | 2023-2025 | Orbactiv, Kimyrsa, Rezzayo |
| Gilead Sciences, INC. | $62.97 | 2024-2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calliditas Therapeutics US INC. | $55.90 | 2023-2025 | Tarpeyo |
| Novo Nordisk INC | $52.17 | 2025 | Ozempic |
| Glaxosmithkline, LLC. | $43.15 | 2022-2023 | Benlysta |
| Fresenius USA Manufacturing, INC. | $23.53 | 2025 | |
| La Jolla Pharmaceutical Company | $21.06 | 2023 | Xerava |
| Alexion Pharmaceuticals, INC. | $19.54 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Chu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.